These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22197861)

  • 21. Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors.
    Uguen A; Conq G; Doucet L; Talagas M; Costa S; De Braekeleer M; Marcorelles P
    Virchows Arch; 2015 Jul; 467(1):47-54. PubMed ID: 25823616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study.
    Veras E; Malpica A; Deavers MT; Silva EG
    Int J Gynecol Pathol; 2009 Jul; 28(4):316-21. PubMed ID: 19483635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
    Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
    Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.
    Hale CS; Qian M; Ma MW; Scanlon P; Berman RS; Shapiro RL; Pavlick AC; Shao Y; Polsky D; Osman I; Darvishian F
    Am J Surg Pathol; 2013 Jun; 37(6):882-9. PubMed ID: 23629443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients.
    Ponti G; Pollio A; Cesinaro AM; Pellacani G; Magnoni C; Seidenari S
    Cancer Epidemiol; 2012 Jun; 36(3):303-5. PubMed ID: 22153914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of tumor mitotic rate in thin metastatic melanomas compared with thin melanomas without metastasis using both the hematoxylin and eosin and anti-phosphohistone 3 IHC stain.
    Thareja S; Zager JS; Sadhwani D; Thareja S; Chen R; Marzban S; Jukic DM; Glass LF; Messina J
    Am J Dermatopathol; 2014 Jan; 36(1):64-7. PubMed ID: 24451214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.
    Tetzlaff MT; Curry JL; Ivan D; Wang WL; Torres-Cabala CA; Bassett RL; Valencia KM; McLemore MS; Ross MI; Prieto VG
    Mod Pathol; 2013 Sep; 26(9):1153-60. PubMed ID: 23558574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in tumor thickness between hematoxylin and eosin and Melan-A immunohistochemically stained primary cutaneous melanomas.
    Drabeni M; Lopez-Vilaró L; Barranco C; Trevisan G; Gallardo F; Pujol RM
    Am J Dermatopathol; 2013 Feb; 35(1):56-63. PubMed ID: 22688397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
    Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
    Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Automated quantification of Ki67/MART1 stains may prevent false-negative melanoma diagnoses.
    Wandler A; Spaun E; Steiniche T; Nielsen PS
    J Cutan Pathol; 2016 Nov; 43(11):956-962. PubMed ID: 27461337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
    Ladstein RG; Bachmann IM; Straume O; Akslen LA
    BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.
    Nielsen PS; Riber-Hansen R; Schmidt H; Steiniche T
    Diagn Pathol; 2016 Apr; 11():35. PubMed ID: 27062658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Utility of Phosphohistone H3 in Breast Cancer Grading.
    Cui X; Harada S; Shen D; Siegal GP; Wei S
    Appl Immunohistochem Mol Morphol; 2015; 23(10):689-95. PubMed ID: 25611243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The potential value of phosphohistone-h3 mitotic index determined by digital image analysis in the assessment of pancreatic endocrine tumors in fine-needle aspiration cytology specimens.
    Draganova-Tacheva R; Bibbo M; Birbe R; Daskalakis C; Solomides C
    Acta Cytol; 2013; 57(3):291-5. PubMed ID: 23635399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas.
    Duregon E; Bertero L; Pittaro A; Soffietti R; Rudà R; Trevisan M; Papotti M; Ventura L; Senetta R; Cassoni P
    Oncotarget; 2016 Apr; 7(16):21190-8. PubMed ID: 27049832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitotic rate in cutaneous melanomas ≤1 mm in thickness: a prospective study.
    Litzner BR; Etufugh CN; Stepenaskie S; Hynan LS; Cockerell CJ
    Am J Dermatopathol; 2012 Dec; 34(8):827-32. PubMed ID: 22878366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.
    Gimotty PA; Van Belle P; Elder DE; Murry T; Montone KT; Xu X; Hotz S; Raines S; Ming ME; Wahl P; Guerry D
    J Clin Oncol; 2005 Nov; 23(31):8048-56. PubMed ID: 16258103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
    Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
    Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How staging of thin melanoma is changed after the introduction of TNM 7th edition: a population-based analysis.
    Caldarella A; Fancelli L; Manneschi G; Chiarugi A; Nardini P; Crocetti E
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):73-6. PubMed ID: 26113451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody.
    Medani H; Elshiekh M; Naresh KN
    J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.